Biolife solutions receives nasdaq notice of noncompliance for delayed 10-k filing

Bothell, wash. , march 18, 2022 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (cgt) and biopharma markets, announced today that it has received a notice ("notice") from the listing qualifications department of the nasdaq stock market ("nasdaq") as a result of its failure to timely file its annual report on form 10-k for the year ended december 31, 2021 (the "form 10-k").
BLFS Ratings Summary
BLFS Quant Ranking